What is it about?
Reviewing available litterature and clinical trials using Letermovir for prophylaxis or treatment of CMV disease in stem cell and solid organ transplant recipients
Featured Image
Why is it important?
CMV is a major cause of morbidity and mortality following stem cell and solid organ transplant, especially in select high risk patients. Preventing and treating CMV remains a very important part of the management of post transplant period
Perspectives
Letermovir has earned its place in high risk HSCT recipients for CMV ppx. Will this expand to SOT?
Dr Guy El Helou
Mayo Foundation
Read the Original
This page is a summary of: Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review, Infection and Drug Resistance, June 2019, Dove Medical Press,
DOI: 10.2147/idr.s180908.
You can read the full text:
Contributors
The following have contributed to this page
